News - GlaxoSmithKline, Relvar Ellipta

Filter

Popular Filters

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

11-06-2014

UK pharma giant GlaxoSmithKline and US partner Theravance have released positive results from two Phase…

Breo ElliptaGlaxoSmithKlineIncruse ElliptaPharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryTheravance

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

08-01-2014

UK pharma giant GlaxoSmithKline and US partner Theravance today announced the launch of Relvar Ellipta…

GlaxoSmithKlineMarkets & MarketingNorthern EuropePharmaceuticalRelvar ElliptaRespiratory and PulmonaryTheravanceUK

Relvar Ellipta approved for asthma and COPD in Europe

Relvar Ellipta approved for asthma and COPD in Europe

19-11-2013

The European Commission has granted marketing authorization for Relvar Ellipta (fluticasone furoate/vilanterol…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Back to top